After seven months of clinical investigation, Validcare, a research software and services

company, announced March 22 that its team of principal investigators met with

members of the U.S. Food and Drug Administration’s Cannabis Product Council

(formerly known as the Cannabis Work Group) to share initial findings from the

industry-sponsored, decentralized human safety study of hemp-derived CBD products.

Preliminary findings showed no evidence of liver disease and no increase in the

prevalence of elevated liver function tests in adults who ingest oral CBD products when

compared to a population with a similar incidence of medical conditions.